Last Updated: November 16, 2026

SELARSDI Drug Profile

« Back to Dashboard


Summary for Tradename: SELARSDI
High Confidence Patents:0
Applicants:1
BLAs:1
Pharmacology for SELARSDI
Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

  1. Brand-side disclosures in response to biosimilar applications
  2. These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

  3. DrugPatentWatch analysis and company disclosures
  4. These patents were identified from searching various sources, including drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

  5. Patents from broad patent text search
  6. For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for SELARSDI Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for SELARSDI Derived from DrugPatentWatch Analysis and Company Disclosures

No patents found based on company disclosures

3) Low Certainty: US Patents for SELARSDI Derived from Patent Text Search

No patents found based on company disclosures

SELARSDI Market Dynamics, Patent Position, and Financial Trajectory

Last updated: October 29, 2026

SELARSDI is Teva Pharmaceuticals and Alvotech's ustekinumab biosimilar, marketed under the active ingredient name ustekinumab-aekn. The product competes with Johnson & Johnson's Stelara in psoriasis, psoriatic arthritis, Crohn's disease, and ulcerative colitis. Its commercial opportunity is substantial because Stelara generated more than $10 billion in annual global sales before biosimilar competition, but SELARSDI's financial contribution is not separately disclosed.

The principal value drivers are U.S. launch access, interchangeable-biosimilar status, payer contracting, net price discipline, manufacturing scale, and the number of competing ustekinumab biosimilars. The principal risks are rapid price erosion, formulary exclusion, competing products from Amgen, Celltrion, Samsung Bioepis, Sandoz and others, and limited standalone revenue visibility in Teva's public reporting.

What is SELARSDI and who markets it?

SELARSDI is the U.S. brand name for ustekinumab-aekn, a biosimilar to Stelara. Alvotech developed the product, while Teva is responsible for U.S. commercialization under its partnership with Alvotech.

Attribute SELARSDI
Active ingredient Ustekinumab-aekn
Reference product Stelara
Reference-product sponsor Janssen Biotech, a Johnson & Johnson company
Biosimilar developer Alvotech
U.S. commercial partner Teva Pharmaceuticals
FDA pathway Section 351(k) biosimilar pathway
Main indications Plaque psoriasis, psoriatic arthritis, Crohn's disease and ulcerative colitis
Dosage forms Subcutaneous prefilled syringe and vial presentations, depending on approved presentation
FDA approval April 2024
Interchangeability FDA status must be confirmed against the current Purple Book and product labeling before substitution decisions

The FDA approved SELARSDI based on analytical, pharmacokinetic, clinical immunogenicity and comparative efficacy data supporting biosimilarity to Stelara.[1] The product is intended to compete across both dermatology and gastroenterology channels.

When did SELARSDI launch in the United States?

Teva and Alvotech reached a settlement with Johnson & Johnson that permitted U.S. commercialization of their ustekinumab biosimilar in 2025, subject to the settlement's terms.[2] Teva reported the launch of SELARSDI in the U.S. during 2025.

The commercial launch occurred after Stelara's core regulatory exclusivity had expired and after patent litigation and settlement negotiations established an authorized entry window. U.S. market access was therefore available earlier than a fully litigated patent loss would have required, but the launch was not unconstrained. Entry was shaped by the settlement, manufacturing readiness, payer contracts and competitors' launch schedules.

How large is the Stelara market available to SELARSDI?

Stelara generated approximately $10.9 billion in worldwide sales for Johnson & Johnson in 2023.[3] U.S. sales represented the largest portion of the franchise and provide the primary near-term opportunity for SELARSDI.

The addressable market is divided across four principal indications:

  1. Plaque psoriasis, including moderate-to-severe disease.
  2. Active psoriatic arthritis.
  3. Moderately to severely active Crohn's disease.
  4. Moderately to severely active ulcerative colitis.

Dermatology demand is relatively concentrated among specialty pharmacies and large insurers. Gastroenterology demand is more dependent on treatment sequencing, prior authorization, infusion-center economics, and physician familiarity with biologic switching. This creates different adoption patterns by indication.

Market factor Impact on SELARSDI
Stelara reference sales Creates a large switching and new-start opportunity
Multiple biosimilar entrants Accelerates price competition
Interchangeability Can improve pharmacy-level substitution where applicable
Specialty distribution Limits the relevance of ordinary retail pharmacy substitution
Gastroenterology use Supports durable volume but can slow switching
Dermatology use Can support faster adoption through specialty-pharmacy contracts
Payer concentration Gives large insurers significant negotiating power
Teva commercial infrastructure Reduces launch and distribution costs

What is the financial trajectory for SELARSDI?

Teva does not generally report SELARSDI revenue as a standalone line item. Public financial statements therefore do not establish product-specific sales, gross margin, market share or earnings contribution.

The expected financial trajectory has four stages:

Launch and access-building phase

Initial revenue depends on contracting with national and regional payers, specialty pharmacies, integrated delivery networks and gastroenterology distributors. Early sales are likely to reflect stocking, conversion programs and new patient starts rather than mature market share.

Share capture phase

Revenue growth should depend more on volume than price. The presence of several ustekinumab biosimilars will make deep discounts likely, particularly for large commercial plans and government-related channels. A product with modest unit share can still generate material revenue if it secures preferred formulary placement.

Price-erosion phase

Ustekinumab biosimilar pricing will likely follow the pattern established by other mature biologic classes: rapid discounting at the payer-contract level, followed by broader net-price compression. List-price comparisons may overstate the actual economics because rebates and performance-based discounts are not fully visible.

Mature portfolio phase

Long-term profitability will depend on manufacturing cost, supply reliability, royalty obligations, commercialization costs and the product's share of Teva's broader biosimilars portfolio. Teva has an established specialty and generic commercial network, but biosimilar economics require sustained volume and disciplined production costs.

A reasonable commercial interpretation is that SELARSDI is strategically important as a portfolio product but is unlikely to become a separately material companywide revenue driver unless Teva secures a leading U.S. share or expands commercialization into additional territories.

How does SELARSDI compare with Stelara financially?

Stelara retains advantages in brand recognition, physician experience, historical payer coverage and established patient support. SELARSDI has a lower-cost positioning and can compete for payer-preferred status, treatment-naive patients and patients eligible for a biologic switch.

Dimension SELARSDI Stelara
Product status Biosimilar Reference biologic
Sponsor Teva and Alvotech Johnson & Johnson/Janssen
Pricing position Expected lower net price Premium reference-product pricing
Clinical evidence Biosimilar comparability package Original approval and extensive real-world use
Physician familiarity Developing Established
Substitution Depends on FDA interchangeability status and state law Not applicable as reference product
Patent exposure Biosimilar applicant and settlement terms Reference-product patent estate
Revenue disclosure Not separately disclosed Reported by Johnson & Johnson
Main commercial lever Formulary access and price Brand retention and clinical franchise

The main economic contest is not simply whether SELARSDI is clinically similar to Stelara. It is whether Teva can convert similarity into preferred formulary access without giving up too much net price.

What patents and exclusivity protect Stelara against SELARSDI?

Stelara is a biologic, so its relevant FDA listing is generally in the Purple Book rather than the Orange Book. The BPCIA governs biosimilar approval, patent information exchange, litigation and market entry. Orange Book-listed patents and Paragraph IV procedures are associated primarily with small-molecule drug applications under the Hatch-Waxman framework.

Stelara's 12-year U.S. reference-product exclusivity period began with its September 2009 approval and expired in 2021, subject to any applicable pediatric exclusivity.[1] Commercial entry remained constrained by patent disputes involving composition, formulation, manufacturing and method-of-treatment claims.

The settlement between Johnson & Johnson, Teva and Alvotech established an agreed U.S. entry framework. The key commercial effect was to replace a fully litigated launch date with a negotiated entry date and defined rights under the settlement.[2]

What formulation patents matter?

Ustekinumab patent disputes have included claims directed to formulations, dosing regimens, manufacturing processes and methods of treating inflammatory diseases. Formulation patents can matter even after the primary biologic claims expire because they may be asserted against a biosimilar's specific concentration, stabilizer system, container or administration method.

The practical relevance of any particular patent depends on:

  • Claim scope.
  • Validity and enforceability.
  • Whether the biosimilar uses the claimed formulation.
  • Whether the patent is enforceable against the approved presentation.
  • Settlement terms.
  • The geographic market.

A patent number should not be treated as a commercial launch barrier without reviewing the claim language, prosecution history, litigation pleadings and settlement agreement.

Does SELARSDI face Paragraph IV challenges or biosimilar litigation?

SELARSDI is not a conventional Paragraph IV generic because it was approved through the 351(k) biosimilar pathway rather than an abbreviated new drug application. The comparable legal process is the BPCIA patent dance and related patent litigation.

Teva and Alvotech's U.S. entry involved patent litigation and settlement with Johnson & Johnson. The settlement reduced immediate injunction risk but did not eliminate competitive or patent risk in other jurisdictions. It also does not prevent later disputes involving manufacturing changes, additional presentations, new indications or patents that were not resolved by the original agreement.

Other ustekinumab biosimilar developers have pursued U.S. approvals and commercial arrangements. Competition from multiple suppliers increases the probability of formulary price concessions and reduces the likelihood that any one entrant will retain a high biosimilar margin.

Which companies compete with SELARSDI?

The competitive field includes originator Stelara and multiple ustekinumab biosimilar programs. Known participants have included Alvotech and Teva, Amgen, Celltrion, Samsung Bioepis, Sandoz and other developers pursuing regional or global approvals.

Competition differs by market. A company may have U.S. approval but lack European approval, or may hold rights through a licensing arrangement rather than direct commercialization. Manufacturing capacity and settlement dates can be as important as FDA approval status.

Competitive category Companies or products
Reference product Stelara, Janssen
SELARSDI sponsors Teva and Alvotech
Other biosimilar developers Amgen, Celltrion, Samsung Bioepis, Sandoz and others
Commercial differentiators Price, interchangeability, supply, payer access and physician education

What generic-entry and biosimilar risks exist?

SELARSDI's principal risk is not generic substitution in the traditional small-molecule sense. It is accelerated biologic switching driven by payer mandates, specialty-pharmacy protocols and contracting.

The main risks are:

  • Lower-than-expected formulary placement.
  • Greater-than-expected rebate requirements.
  • Delayed adoption by gastroenterologists.
  • Manufacturing interruptions.
  • Limited capacity for multiple approved presentations.
  • Additional biosimilar entrants.
  • State-law limits on interchangeable substitution.
  • Physician resistance to nonmedical switching.
  • Patent or regulatory disputes involving new formulations.
  • Margin dilution caused by price competition.

The strongest defense is reliable supply at a competitive net price. Clinical differentiation is limited because the product must be highly similar to Stelara.

What is the international market outlook?

Outside the United States, market access depends on national biosimilar rules, reimbursement policy, substitution standards, tender systems and patent status. Europe generally has more mature biosimilar adoption mechanisms, but the commercial model can be less profitable because hospital tenders and centralized procurement place direct pressure on price.

Teva and Alvotech can capture additional value through regional licensing, distributor arrangements and local reimbursement access. Geographic expansion will require country-specific approval, pharmacovigilance systems and supply-chain compliance. A successful U.S. launch does not establish equivalent pricing or market share in Europe, Canada, Japan or emerging markets.

How strong is the SELARSDI patent and commercial position?

SELARSDI is not primarily protected by a conventional product patent estate because its value comes from biosimilar approval, regulatory interchangeability where granted, manufacturing know-how, settlement rights and commercial execution.

Its commercial position is moderate:

  • Regulatory risk is lower after FDA approval.
  • Patent-launch risk is reduced by the Johnson & Johnson settlement.
  • Pricing risk is high because several competitors are entering the same market.
  • Manufacturing risk remains material because biologics require validated processes and reliable cold-chain distribution.
  • Revenue visibility is low because Teva does not separately disclose SELARSDI sales.
  • Long-term value depends on share and net price, not patent exclusivity.

Key Takeaways

  • SELARSDI is Teva and Alvotech's ustekinumab-aekn biosimilar to Stelara.
  • FDA approval was granted in April 2024 for Stelara's principal dermatology and gastrointestinal indications.
  • U.S. commercialization began under a settlement-based entry framework in 2025.
  • Stelara generated roughly $10.9 billion in global sales in 2023, creating a large but highly competitive opportunity.
  • Teva does not separately report SELARSDI revenue, so product-specific financial performance cannot be independently quantified from public company filings.
  • Price, formulary position, supply reliability and switching policy will determine commercial performance.
  • Stelara is governed by the Purple Book and BPCIA framework rather than the standard Orange Book and Paragraph IV model.
  • Multiple competing ustekinumab biosimilars create substantial risk of rapid net-price erosion.

FAQs

Is SELARSDI the same drug as Stelara?

SELARSDI is a biosimilar to Stelara, not the original reference product. FDA approval requires no clinically meaningful differences in safety, purity and potency between the biosimilar and reference biologic.

Is SELARSDI interchangeable with Stelara?

Interchangeability depends on the FDA's current Purple Book designation and approved labeling. Substitution also depends on applicable state pharmacy laws and payer policies.

Who owns SELARSDI?

Alvotech developed the product, and Teva holds U.S. commercialization rights under their partnership.

Will SELARSDI reduce Stelara revenue?

It is expected to pressure Stelara volume and net pricing, but the effect will depend on payer formularies, physician switching behavior and the number of competing biosimilars.

Does SELARSDI have its own patent?

The product's commercial protection is primarily based on regulatory approval, manufacturing technology, settlement rights and market execution. Any relevant formulation, process or method patents must be assessed claim by claim.

References

  1. U.S. Food and Drug Administration. (2024). SELARSDI (ustekinumab-aekn) prescribing information and approval materials.
  2. Teva Pharmaceutical Industries Ltd. (2023). Teva and Alvotech announce settlement and license agreement with Janssen for AVT04 in the United States.
  3. Johnson & Johnson. (2024). 2023 annual report.

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.